Sorry - There were no pages found that contain that search phrase.
 |
|
|
|
|
|
Showing Treatment 1 to 25 of 81 Next 25 |
|
Location |
|
Last Updated |
|
|
|
Details |
|
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
|
Pittsburgh, PA USA |
|
09/30/2009 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
|
Danville, PA USA |
|
09/30/2009 |
|
|
|
Details |
|
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Newly Diagnosed Malignant or Intrinsic Brain Stem Gliomas (BSG) or Incompletely Resected Non-Brainstem High-Grade Gliomas (HGG) or Recurrent Unresectable Low-Grade Gliomas (LGG) or Recurrent High Grade Gliomas |
|
Pittsburgh, PA USA |
|
09/23/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Philadelphia, PA USA |
|
04/21/2009 |
|
|
|
Details |
|
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 (MAb-425) in High Grade Gliomas |
|
Philadelphia, PA USA |
|
02/12/2009 |
|
|
|
|
|
Details |
|
Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) |
|
Philadelphia, PA USA |
|
01/31/2009 |
|
|
|
Details |
|
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Adults with High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas |
|
Pittsburgh, PA USA |
|
01/06/2009 |
|
|
|
|
|
Details |
|
Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
|
|
Philadelphia, PA USA |
|
11/08/2008 |
|
|
|
Details |
|
Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
|
|
Pittsburgh, PA USA |
|
11/08/2008 |
|
|
|
|
|
Details |
|
Phase I Trial of Aflibercept (VEGF Trap)with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Gliomas |
|
Pittsburgh, PA USA |
|
10/27/2008 |
|
|
|
Details |
|
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma |
|
Pittsburgh, PA USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Wynnewood, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Philadelphia, PA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Bryn Mawr, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Philadelphia, PA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Philadelphia, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Allentown, PA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Paoli, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Reading, PA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
|
Bethlehem, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas |
|
Pittsburgh, PA USA |
|
03/02/2008 |
|
|
|
Details |
|
NABTC 04-02: Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
|
|
Pittsburgh, PA USA |
|
10/03/2007 |
|
|
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
|
|
